NEWS
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apollomics presented promising data on vebreltinib at the 2024 ASCO Annual Meeting. The Phase 2 and 2/3 trials showed strong efficacy and safety in treating MET-altered tumors, particularly in non-small cell lung cancer (NSCLC) and glioblastoma patients. Key results included a 75% overall response rate (ORR) for NSCLC with MET exon 14-skipping mutations, and a 6.31 months median overall survival (OS) in glioblastoma patients with PTPRZ1-MET Fusion gene. No new safety concerns were identified. Apollomics aims to continue advancing vebreltinib's clinical development.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1259Followers
76Following
8849Visitors
Follow